Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
90 hedge funds and large institutions have $337M invested in Stemline Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
31% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 26
11% more capital invested
Capital invested by funds: $303M → $337M (+$34.2M)
1% less funds holding
Funds holding: 91 → 90 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
94% less call options, than puts
Call options by funds: $254K | Put options by funds: $4.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Pier Capital
Stamford,
Connecticut
|
+$4.04M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$2.27M |
| 3 |
BlackRock
New York
|
+$1.87M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.87M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.05M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.32M |
| 4 |
Two Sigma Investments
New York
|
-$1.98M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.47M |
STML Hedge Fund Activity: Q3 2018 in Review
90 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2018, worth a combined $337M — up 11% from $303M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of STML and 8 opened new positions — a net loss of 1 holder — while 26 trimmed existing stakes and 34 added.
The largest buyer was Pier Capital, opening a new position worth an estimated $4.04M. The largest seller was Adage Capital Partners, cutting an estimated $7.21M.
- 90 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2018, down from 91 in Q2 2018.
- Funds reported $337M of Stemline Therapeutics, Inc. stock for Q3 2018, up 11% quarter-over-quarter.
- 8 funds opened new Stemline Therapeutics, Inc. positions in Q3 2018 and 9 closed out, a net change of -1 holder.
- The largest Stemline Therapeutics, Inc. buyer in Q3 2018 was Pier Capital, an estimated $4.04M added.
- The largest Stemline Therapeutics, Inc. seller in Q3 2018 was Adage Capital Partners, an estimated $7.21M sold.
Based on aggregated 13F filings for Q3 2018.